Management of hyperuricemia in asymptomatic patients: a critical appraisal
A Brucato, F Cianci, C Carnovale - European Journal of Internal Medicine, 2020 - Elsevier
While there is consensus on starting urate-lowering therapy (ULT) in cases of symptomatic
hyperuricemia, the frequent condition of asymptomatic hyperuricemia (AH) remains a …
hyperuricemia, the frequent condition of asymptomatic hyperuricemia (AH) remains a …
[HTML][HTML] Gout–a guide for the general and acute physicians
A Abhishek, E Roddy, M Doherty - Clinical Medicine, 2017 - Elsevier
Gout is the most prevalent inflammatory arthritis and affects 2.5% of the general population
in the UK. It is also the only arthritis that has the potential to be cured with safe, inexpensive …
in the UK. It is also the only arthritis that has the potential to be cured with safe, inexpensive …
Alcohol quantity and type on risk of recurrent gout attacks: an internet-based case-crossover study
T Neogi, C Chen, J Niu, C Chaisson, DJ Hunter… - The American journal of …, 2014 - Elsevier
Objectives Although beer and liquor have been associated with risk of incident gout, wine
has not. Yet anecdotally, wine is thought to trigger gout attacks. Further, how much alcohol …
has not. Yet anecdotally, wine is thought to trigger gout attacks. Further, how much alcohol …
[HTML][HTML] Global, regional, and national prevalence of gout from 1990 to 2019: age-period-cohort analysis with future burden prediction
Q He, TN Mok, TH Sin, J Yin, S Li, Y Yin… - JMIR Public Health …, 2023 - publichealth.jmir.org
Background: Gout is a common and debilitating condition that is associated with significant
morbidity and mortality. Despite advances in medical treatment, the global burden of gout …
morbidity and mortality. Despite advances in medical treatment, the global burden of gout …
Colchicine: its mechanism of action and efficacy in crystal-induced inflammation
G Nuki - Current rheumatology reports, 2008 - Springer
New light has been shed on the mechanisms of action of colchicine in crystal-associated
arthropathies. Colchicine, long used to treat gout, arrests microtubule assembly and inhibits …
arthropathies. Colchicine, long used to treat gout, arrests microtubule assembly and inhibits …
Management of gout: a systematic review in support of an American College of Physicians clinical practice guideline
PG Shekelle, SJ Newberry, JD FitzGerald… - Annals of internal …, 2017 - acpjournals.org
Background: Gout is a common type of inflammatory arthritis in patients seen by primary
care physicians. Purpose: To review evidence about treatment of acute gout attacks …
care physicians. Purpose: To review evidence about treatment of acute gout attacks …
The association of dietary intake of purine-rich vegetables, sugar-sweetened beverages and dairy with plasma urate, in a cross-sectional study
Introduction Hyperuricemia is a strong risk factor for gout. The incidence of gout and
hyperuricemia has increased recently, which is thought to be, in part, due to changes in diet …
hyperuricemia has increased recently, which is thought to be, in part, due to changes in diet …
Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney
JN Miner, PK Tan, D Hyndman, S Liu, C Iverson… - Arthritis research & …, 2016 - Springer
Background Excess body burden of uric acid promotes gout. Diminished renal clearance of
uric acid causes hyperuricemia in most patients with gout, and the renal urate transporter …
uric acid causes hyperuricemia in most patients with gout, and the renal urate transporter …
Increased risk of vascular disease associated with gout: a retrospective, matched cohort study in the UK clinical practice research datalink
LE Clarson, SL Hider, J Belcher, C Heneghan… - Annals of the …, 2015 - ard.bmj.com
Objectives To determine whether gout increases risk of incident coronary heart disease
(CHD), cerebrovascular (CVD) and peripheral vascular disease (PVD) in a large cohort of …
(CHD), cerebrovascular (CVD) and peripheral vascular disease (PVD) in a large cohort of …
A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300–600 mg/day versus benzbromarone 100–200 mg/day in patients …
MK Reinders, C Haagsma, TLTA Jansen… - Annals of the …, 2009 - ard.bmj.com
Objectives: To compare the efficacy and tolerability of allopurinol 300–600 mg/day versus
benzbromarone 100–200 mg/day used to attain a target serum urate concentration (sUr)⩽ …
benzbromarone 100–200 mg/day used to attain a target serum urate concentration (sUr)⩽ …